Global genome engineering market is estimated to be valued at USD 6.71 Bn in 2024, and is expected to exhibit a CAGR of 14.5% during the forecast period (2024-2031). Genome engineering, also known as genetic engineering, is a set of technologies that enable genetic manipulation and editing of an organism's genes. It involves the alteration of an organism's genetic makeup, including the transfer of genes within and across species boundaries to produce improved or novel organisms. Genome engineering utilizes technologies such as CRISPR/Cas9, TALENs, ZFNs and other DNA targeting nucleases to enable targeted genome editing and modification. Researchers have successfully utilized these technologies for crop improvement and experimental investigation of gene function in various organisms. Global genome engineering market is expected to witness growth due to increasing adoption of genome technologies in various industries.

Market Dynamics:

Global genome engineering market growth is driven by rising application of genetic engineering in areas of biotechnology, pharmaceuticals and agriculture. Genome editing tools such as CRISPR have provided researchers unparalleled precision to easily alter DNA sequences and modify gene function, fueling growth opportunities. Growing investment by key players and governments in genome engineering-based research can drive the market growth. However, uncertainties related to safety and ethics of human gene editing can pose a challenge to market players. Increasing R&D for developing more accurate and efficient genome engineering tools is expected to offer new opportunities for the market growth. Exploration of novel applications areas such as environmental remediation and energy production also hold immense potential for market growth in the near future.

Key Features of the Study:

• This report provides an in-depth analysis of the global genome engineering market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global genome engineering market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., Merck KGaA, New England Biolabs, Agilent Technologies, Inc., Genscript, Synbio Technologies, Creative Biogene, Eurofins Scientific, Regeneron Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global genome engineering market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genome engineering market.

Detailed Segmentation-

• By Technology:
  • CRISPR
  • TALEN
  • ZFN
  • Others
• By Application:
  • Cell Line Engineering
  • Genetic Engineering
• By End User:
  • Biotechnology & Pharmaceutical Companies
  • Research Institutes
  • Contract Research Organizations
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Company Profiles:

• Thermo Fisher Scientific Inc.
• CRISPR Therapeutics AG
• Intellia Therapeutics, Inc.
• Editas Medicine, Inc.
• Sangamo Therapeutics, Inc.
• Bluebird Bio, Inc.
• Cellectis S.A.
• Merck KGaA
• New England Biolabs
• Agilent Technologies, Inc.
• Genscript
• Synbio Technologies
• Creative Biogene
• Eurofins Scientific
• Regeneron Pharmaceuticals Inc.